A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease

No abstract is available for this paper.

• Publication year

  2006

• Venue

  International Journal of Geriatric Psychiatry

• Publication date

  2006-01-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1002/GPS.1402PMID 16323253
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.

  2006cited by this paper
• Donepezil for dementia due to Alzheimer's disease.

  2006cited by this paper
• The impact of NICE guidelines on the diagnosis and treatment of Alzheimer's disease among general medical hospital inpatients

  2004cited by this paper
• The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease

  2004cited by this paper
• Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.

  2004cited by this paper
• A multinational, randomised, 12‐week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease

  2004cited by this paper
• Reduction of behavioral disturbances and caregiver distress by galantamine in patients with Alzheimer's disease.

  2004influential reference
• P.4.046 Donepezil-treated Alzheimer's disease patients with apparent initial cognitive decline demonstrate significant benefits when therapy is continued: Results from a randomized, placebo-controlled trial

  2003cited by this paper
• Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease.

  2003cited by this paper
• A MULTINATIONAL, RANDOMISED, 12‐WEEK, COMPARATIVE STUDY OF DONEPEZIL AND RIVASTIGMINE IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE

  2002cited by this paper
• Functional, Cognitive and Behavioral Effects of Donepezil in Patients with Moderate Alzheimer's Disease

  2002cited by this paper
• An Economic Evaluation of Donepezil in Mild to Moderate Alzheimer’s Disease: Results of a 1-Year, Double-Blind, Randomized Trial

  2002cited by this paper
• Systematic reviews in health care: Assessing the quality of controlled clinical trials.

  2001cited by this paper
• Cognitive deficits in Alzheimer's disease: treatment with acetylcholinesterase inhibitor agents.

  2001cited by this paper
• [Drug treatments for Alzheimer's disease]

  2001cited by this paper
• A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD

  2001cited by this paper
• Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.

  2001cited by this paper
• Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial

  2001cited by this paper
• A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients

  2001cited by this paper
• Galantamine: a randomized, double‐blind, dose comparison in patients with Alzheimer's disease

  2001cited by this paper
• A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD.

  2001cited by this paper
• Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial

  2000influential reference
• Clinical Efficacy and Safety of Donepezil on Cognitive and Global Function in Patients with Alzheimer’s Disease

  2000cited by this paper
• A 5-month, randomized, placebo-controlled trial of galantamine in AD

  2000cited by this paper
• Galantamine in AD

  2000cited by this paper
• Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension

  2000cited by this paper
• Donepezil therapy in clinical practice: a randomized crossover study.

  2000influential reference
• Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trialCommentary: Another piece of the Alzheimer's jigsaw

  1999cited by this paper
• Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.

  1999cited by this paper
• The Effects of Donepezil in Alzheimer’s Disease – Results from a Multinational Trial1

  1999influential reference
• A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®)

  1999cited by this paper
• Donepezil Improves Cognition and Global Function in Alzheimer Disease A 15-Week, Double-blind, Placebo-Controlled Study

  1998influential reference
• A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease

  1998influential reference
• Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.

  1998cited by this paper
• EFFICACY AND TOLERABILITY OF RIVASTIGMINE IN PATIENTS WITH DEMENTIA OF THE ALZHEIMER TYPE

  1998influential reference
• The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial

  1996cited by this paper
• The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial. The Donepezil Study Group.

  1996cited by this paper

• Effectiveness of acetylcholinesterase inhibitors and memantine in patients affected by severe dementia.

  2025cites this paper
• SAHRANG: Subarachnoid Hemorrhage Recovery and Galantamine: A Pilot Multicenter Randomized Placebo-Controlled Trial

  2025cites this paper
• Development of novel rivastigmine derivatives as selective BuChE inhibitors for the treatment of AD.

  2025cites this paper
• Rapid health technology assessment of galantamine for the treatment of Alzheimer’s disease: A review

  2025cites this paper
• Targeting the serotonergic system in the treatment of neurodegenerative diseases—emerging therapies and unmet challenges

  2025cites this paper
• SAHRANG: Subarachnoid Hemorrhage Recovery and Galantamine - A pilot multicenter randomized placebo-controlled trial

  2025cites this paper
• Cholinesterase Inhibitory Activity, Gas Chromatography‐Mass Spectrometry Profiling, and In Silico Studies on the Selected Artemisia Essential Oils

  2025cites this paper
• Relationship between the response to donepezil and plasma amyloid beta oligomers in patients with Alzheimer's disease

  2024cites this paper
• Efficacy of Rivastigmine Augmentation on Positive and Negative Symptoms, General Psychopathology, and Quality of Life in Patients with Chronic Schizophrenia: A Randomized Controlled Trial.

  2024cites this paper
• Development of novel fluoro-substituted rivastigmine derivatives as selective AChE inhibitors for the treatment of AD

  2024cites this paper
• Non-competitive inhibition of acetylcholinesterase by jaboticaba (Myrciaria cauliflora) peel ethanolic extracts

  2024cites this paper
• Types of memory, dementia, Alzheimer's disease, and their various pathological cascades as targets for potential pharmacological drugs.

  2024cites this paper
• Galantamine for dementia due to Alzheimer's disease and mild cognitive impairment.

  2024cites this paper
• Establishing Reference Values for a New Computerized Cognitive Function Test Program for Children.

  2024cites this paper
• Phenyldiazenyl-phenoxy-1,2,3-triazol-acetamide derivatives as new dual cholinesterase Inhibitors: design, synthesis, in vitro, and in silico enzymatic inhibition evaluations

  2024cites this paper
• Behavioral and Biochemical Effects of an Arylhydrazone Derivative of 5-Methoxyindole-2-Carboxylic Acid in a Scopolamine-Induced Model of Alzheimer’s Type Dementia in Rats

  2024cites this paper
• Comparative in silico analysis of CNS-active molecules targeting the blood–brain barrier choline transporter for Alzheimer’s disease therapy

  2024cites this paper
• Novel acetylcholinesterase inhibitors: Synthesis, docking and inhibitory activity evaluation of 4-benzamido-N-(1-benzylpiperidin-4-yl) benzamide derivatives

  2024cites this paper
• Therapeutic and medicinal effects of snowdrop (Galanthus spp.) in Alzheimer's disease: A review

  2023cites this paper
• Selective modulation of alkali metal ions on acetylcholinesterase.

  2023cites this paper
• Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer’s Disease and Parkinson’s Dementia: Systematic Review and Meta-Analysis

  2023cites this paper
• Effect of Acetylcholinesterase Inhibitors on the Cognitive Impairments in Transgenic Drosophila Model of Alzheimer’s Disease

  2023cites this paper
• Acetyl-cholinesterase-inhibitors slow cognitive decline and decrease overall mortality in older patients with dementia

  2022cites this paper
• Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease

  2022cites this paper
• Protocol for SYNchronising Exercises, Remedies in GaIt and Cognition at Home (SYNERGIC@Home): feasibility of a home-based double-blind randomised controlled trial to improve gait and cognition in individuals at risk for dementia

  2022cites this paper
• WBI Studies Repository WBI Studies Clinical trials and late-stage drug development in Alzheimer’s Clinical trials and late-stage drug development in Alzheimer’s disease: An appraisal from 1984 to 2014 disease: An appraisal from 1984 to 2014

  2022cites this paper
• Racial/ethnic disparities in initiation and persistent use of anti‐dementia medications

  2022cites this paper
• Iranian Thyme honey plays behavioral, cellular and molecular important roles as an amazing preventive and therapeutic agent in the brain of Alzheimer's rat model.

  2022cites this paper
• Alzheimer's Disease THErapy With NEuroaid (ATHENE): A Randomized Double-Blind Delayed-Start Trial.

  2021cites this paper
• ATTENTION, CONCENTRATION & INFORMATION PROCESSING POST ACQUIRED BRAIN INJURY

  2021cites this paper
• Gauging the role and impact of drug interactions and repurposing in neurodegenerative disorders

  2021cites this paper
• Pharmacological Management of Dementia—An Overview

  2021cites this paper
• Chronic Beneficial Effect of Makeup Therapy on Cognitive Function of Dementia and Facial Appearance Analyzed by Artificial Intelligence Software

  2021cites this paper
• Effects of dance intervention on agitation and cognitive functioning of people living with dementia in institutional care facilities: Systematic review.

  2021cites this paper
• This is a repository copy of Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record

  2021cites this paper
• Preventing Dementia? Interventional Approaches in Mild Cognitive Impairment.

  2021cites this paper
• Efficacy of Acetylcholinesterase Inhibitors on Cognitive Function in Alzheimer’s Disease. Review of Reviews

  2021cites this paper
• The need to show minimum clinically important differences in Alzheimer's disease trials.

  2021cites this paper
• The Alzheimer’s disease clinical trials need to demonstrate minimum clinically important differences

  2021cites this paper
• The Efficacy and Safety of Alzheimer’s Disease Therapies: An Updated Umbrella Review

  2021cites this paper
• The Alzheimer’s Disease THErapy with NEuroaid II (ATHENE) Study: A Double-Blind Randomized Delayed-Start Trial to Assess the Safety and E�cacy of MLC901 (NeuroAiD™II) as an add-on Treatment to Cholinesterase Inhibitors or Memantine in Patients With Mild to Moderate Alzheimer's Disease

  2021cites this paper
• Mitochondria in the Cerebral and Cerebellar Cortex in Alzheimer’s Disease, Target for a Therapeutic Approach

  2021cites this paper
• Global Mapping of Interventions to Improve Quality of Life of Patients with Alzheimer’s Disease during 1990–2018

  2020cites this paper
• [Alzheimer disease].

  2020cites this paper
• Using practice effects for targeted trials or sub-group analysis in Alzheimer’s disease: How practice effects predict change over time

  2020cites this paper
• The efficacy and safety of hachimijiogan for mild Alzheimer disease in an exploratory, open standard treatment controlled, randomized allocation, multicenter trial

  2020cites this paper
• Real-world effectiveness, its predictors and onset of action of cholinesterase inhibitors and memantine in dementia: retrospective health record study

  2020cites this paper
• A Recent Look into Natural Products that Have Potential to Inhibit Cholinesterases and Monoamine Oxidase B: Update on 2010-2019.

  2020cites this paper
• Mind the Gap: bridging the translational gap in the management of schizophrenia by treating the whole person.

  2020cites this paper
• Real-World Effectiveness, Its Predictors and Onset of Action of Cholinesterase Inhibitors and Memantine in Dementia: A Retrospective Health Record Study of 7400 Individuals using the UK CRIS Platform

  2020cites this paper
• The biological pathways of Alzheimer disease: a review

  2020cites this paper
• Multifunctional quinoxaline-hydrazone derivatives with acetylcholinesterase and monoamine oxidases inhibitory activities as potential agents against Alzheimer’s disease

  2020cites this paper
• Modulation of neuroinflammatory pathways by medicinal mushrooms, with particular relevance to Alzheimer's disease

  2020cites this paper
• Identification of N-phenyl-3-methoxy-4-pyridinones as orally bioavailable H3 receptor antagonists and β-amyloid aggregation inhibitors for the treatment of Alzheimer's disease.

  2020cites this paper
• Present Algorithms and Future Treatments for Alzheimer’s Disease

  2019cites this paper
• Alkaloids as Potential Multi-Target Drugs to Treat Alzheimer's Disease

  2019cites this paper
• Recent Advances in the Quest for Treatment and Management of Alzheimer and Other Dementia

  2019cites this paper
• Peripheral vascular responses to acetylcholine as a predictive tool for response to cholinesterase inhibitors in Alzheimer’s disease

  2019cites this paper
• COMPARATIVE EFFECTS OF TOLFENAMIC ACID AND DONEPEZIL ON BEHAVIOR AND TAU PATHOLOGY BIOMARKER LEVELS

  2019cites this paper
• Pragmatic Trials and Repurposed Drugs for Alzheimer Disease.

  2019cites this paper
• Spirocyclohexadienones as an Uncommon Scaffold for Acetylcholinesterase Inhibitory Activity.

  2019cites this paper
• Alzheimer’s Disease: Neurotransmitters Involved and the Possible New Strategies

  2019cites this paper
• University of Dundee Peripheral Vascular Responses to Acetylcholine as a Predictive Tool for Response to Cholinesterase Inhibitors in Alzheimer ' s Disease

  2019cites this paper
• 4-Substituted 2-amino-3,4-dihydroquinazolines with a 3-hairpin turn side chain as novel inhibitors of BACE-1.

  2019cites this paper
• Comparisons between traditional medicines and pharmacotherapies for Alzheimer disease: A systematic review and meta‐analysis of cognitive outcomes

  2018cites this paper
• Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease.

  2018cites this paper
• A Computer-Assisted Systematic Search for Melatonin Derivatives with High Potential as Antioxidants

  2018cites this paper
• Is Preservation of Cholinergic Activation a Mechanism Underlying Cognitive Reserve

  2018cites this paper
• Effects of galantamine on smoking behavior and cognitive performance in treatment‐seeking smokers prior to a quit attempt

  2018cites this paper
• Preparation of 4-Flexible Amino-2-Arylethenyl-Quinoline Derivatives as Multi-Target Agents for the Treatment of Alzheimer’s Disease

  2018cites this paper
• Enhancement of the Neuroprotective Effect of Fermented Spirulina maxima Associated with Antioxidant Activities by Ultrasonic Extraction

  2018cites this paper
• A comparison of the effects between 2 computerized cognitive training programs, Bettercog and COMCOG, on elderly patients with MCI and mild dementia

  2018cites this paper
• Drugs for Dementia and Excess of Hospitalization: A Longitudinal French Study

  2018cites this paper
• Gamma-aminobutyric acid A receptors in Alzheimer's disease: highly localized remodeling of a complex and diverse signaling pathway

  2018cites this paper
• SYNERGIC TRIAL (SYNchronizing Exercises, Remedies in Gait and Cognition) a multi-Centre randomized controlled double blind trial to improve gait and cognition in mild cognitive impairment

  2018cites this paper
• Effect of Fermented Spirulina maxima Extract on Cognitive-Enhancing Activities in Mice with Scopolamine-Induced Dementia

  2018cites this paper
• The GABAergic system as a therapeutic target for Alzheimer's disease

  2018cites this paper
• Galantamine and Computerized Cognitive Behavioral Therapy for Cocaine Dependence: A Randomized Clinical Trial.

  2017cites this paper
• Association of Antidementia Drugs and Mortality in Community-Dwelling Frail Older Patients With Dementia: The Role of Mortality Risk Assessment.

  2017cites this paper
• Multifunctional Analogs of Kynurenic Acid for the Treatment of Alzheimer's Disease: Synthesis, Pharmacology, and Molecular Modeling Studies.

  2017cites this paper
• The protection of novel 2-arylethenylquinoline derivatives against impairment of associative learning memory induced by neural Aβ in C. elegans Alzheimer’s disease model

  2017cites this paper
• Design and synthesis of new piperidone grafted acetylcholinesterase inhibitors.

  2017cites this paper
• Assessing Cognitive Phenotypes in Zebrafish

  2017cites this paper
• UvA-DARE ( Digital Academic Repository ) Advancing Translational Research with the Semantic Web

  2017cites this paper
• Alzheimer’s Dementia: An Overview

  2017cites this paper
• Drugs and Drug Delivery Systems Targeting Amyloid-\b{eta} in Alzheimers Disease

  2017cites this paper
• The efficacy of supplementation with the novel medical food, Souvenaid, in patients with Alzheimer's disease: A systematic review and meta-analysis of randomized clinical trials

  2017cites this paper
• Donepezil Plus Solifenacin (CPC-201) Treatment for Alzheimer’s Disease

  2017cites this paper
• Use of Medications of Questionable Benefit at the End of Life in Nursing Home Residents with Advanced Dementia

  2017cites this paper
• Trends in Drug Prescription Rates for Dementia: An Observational Population-Based Study in France, 2006–2014

  2017cites this paper
• Investigation of strategies to ameliorate beta-amyloid mediated deficits in hippocampus-dependent synaptic plasticity

  2016cites this paper
• Donepezil Versus Rivastigmine in Patients with Alzheimer’s Disease: Attention and Working Memory

  2016cites this paper
• Visual Hallucinations Due to Rivastigmine Transdermal Patch Application in Alzheimer's Disease; The First Case Report

  2016cites this paper
• A first principle study on the interaction between acetylcholinesterase and acetylcholine, and also rivastigmine in alzheimer's disease case

  2016cites this paper
• Drug Development of Small-Molecule Inhibitors of AD-Relevant Kinases as Novel Perspective Multitargeted Approach.

  2016cites this paper
• Efficacy of Galantamine on Cognition in Mild-to-Moderate Alzheimer's Dementia after Failure to Respond to Donepezil

  2016cites this paper
• Design, Synthesis and in vitro Evaluation of Indolotacrine Analogues as Multitarget‐Directed Ligands for the Treatment of Alzheimer's Disease

  2016cites this paper
• Novel 1-Phenyl-3-hydroxy-4-pyridinone Derivatives as Multifunctional Agents for the Therapy of Alzheimer's Disease.

  2016cites this paper
• Assessing the perceived differences in post- Galantamine lucid dreams vs. non-Galantamine lucid dreams

  2016cites this paper
• Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine

  2016cites this paper